Vertex gets more precise with Arbor in expanded gene editing pact
Feng Zhang’s Arbor Biotechnologies is expanding its alliance with Vertex Pharmaceuticals, but is staying mum on financials this time around.
The CRISPR gene editing startup, which has been relatively quiet aside from partnership and capital-raising news since its March 2018 unveiling, is providing its Boston partner with access to precision editing technology for in vivo genetic medicines for “up to three diseases.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.